Promotions & Moves

Imvax Appoints Chief Scientific Officer

Mark Exley brings experience in the regulation of the immune system to treat cancer and other diseases

By: Contract Pharma

Contract Pharma Staff

Imvax, Inc. has appointed Mark Exley, PhD, as Chief Scientific Officer, reporting to Chief Executive Officer John Furey. Dr. Exley was previously Vice President, Cellular Immunology for AgenTus. He joins the company as Imvax develops its lead product candidate, IGV-001 for the treatment of newly diagnosed glioblastoma multiforme (GBM). Dr. Exley’s areas of research include natural and vaccine-supported immunity to cancers, immune responses to acute and chronic viral infections, suppr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters